预约演示
更新于：2025-05-29
Adapalene/Benzoyl Peroxide
阿达帕林/过氧苯甲酰
更新于：2025-05-29
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2008-12-08), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C42H38O7 |
InChIKeyUXWMHYHGBDEQJF-UHFFFAOYSA-N |
CAS号1194805-81-6 |
关联
49
项与 阿达帕林/过氧苯甲酰 相关的临床试验TCTR20230810001
A randomized, investigator blind, split-face study of the efficacy of using Eucerin Dermopure to reduce mucocutaneous side effects of adapalene/benzoyl peroxide combination (Epiduo) for the treatment of acne vulgaris.
CTRI/2020/11/028801
A multi-center, double-blind, randomized, placebo controlled, parallel-group study, comparing Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% (Cadila Pharmaceuticals Limited) to Epiduo�® Forte (Adapalene and Benzoyl Peroxide) Gel, 0.3%/2.5%, Galderma Laboratories, L.P.) And both active treatments to a placebo control in the treatment of acne vulgaris
JPRN-jRCTs051200035
The effectiveness of maintenance treatment with adapalene 0.1%-benzoyl peroxide 2.5% gel and benzoyl peroxide 2.5% gel in acne vulgaris patients and the efficacy on acne scar formation
100 项与 阿达帕林/过氧苯甲酰 相关的临床结果
登录后查看更多信息
100 项与 阿达帕林/过氧苯甲酰 相关的转化医学
登录后查看更多信息
100 项与 阿达帕林/过氧苯甲酰 相关的专利（医药）
登录后查看更多信息
34
项与 阿达帕林/过氧苯甲酰 相关的文献（医药）2025-04-01JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
Efficacy of topical treatments for mild‐to‐moderate acne: A systematic review and meta‐analysis of randomized control trials
Review
作者: Young, Trevor ; Nicholson, Joey ; Yassin, Sallie ; Nagler, Arielle R. ; Kakpovbia, Efe E. ; Qian, Yingzhi ; Hu, Jiyuan ; Troxel, Andrea B. ; Milam, Emily C.
Abstract:
Acne is a common skin condition, but little data exist on the comparative efficacy of topical acne therapies. We conducted a systematic review and network meta‐analysis to evaluate the efficacy of topical therapies for mild‐to‐moderate acne. Searches in PubMed/MEDLINE, Cochrane CENTRAL via Ovid, Embase via Ovid and Web of Science were conducted on 29 November 2021. Randomized controlled trials examining ≥12 weeks of topical treatments for acne vulgaris in subjects aged 12 and older were included. Main outcomes were absolute or percent change in acne lesion count and treatment success on the Investigator's Global Assessment scale. Thirty‐five randomized clinical trials with 33,472 participants comparing nine different topical agents were included. Adapalene‐benzoyl peroxide (BPO), clindamycin‐BPO and clindamycin‐tretinoin demonstrated the greatest reduction in non‐inflammatory (ratio of means [RoM] 1.76; 95% CI [1.46; 2.12], RoM 1.70; 95% CI [1.44; 2.02] and RoM 1.87; 95% CI [1.53; 2.30], respectively), inflammatory (RoM 1.56; 95% CI [1.44; 1.70], RoM 1.49; 95% CI [1.39; 1.60] and RoM 1.48; 95% CI [1.36; 1.61], respectively) and total lesion count (ROM 1.67; 95% CI [1.47; 1.90], RoM 1.59; 95% CI [1.42; 1.79] and RoM 1.64; 95% CI [1.42; 1.89], respectively) compared to placebo. All single agents outperformed placebo except tazarotene, which did not significantly outperform placebo for inflammatory and non‐inflammatory lesion count reduction. Most combination agents significantly outperformed their individual components in lesion count reduction and global assessment scores, except for clindamycin‐tretinoin and clindamycin‐BPO, which did not significantly outperform tretinoin (RoM 1.13; 95% CI [0.94; 1.36]) and BPO (RoM = 1.15, 95% CI [0.98; 1.36]), respectively, for non‐inflammatory lesion reduction. There was no significant difference amongst most single agents when evaluating lesion count reduction. Combination agents are generally most effective for mild‐to‐moderate acne; however for non‐inflammatory acne, the addition of clindamycin in topical regimens is unnecessary and should be avoided.
2024-03-01Drug safety
Enhancing Transparency in Defining Studied Drugs: The Open-Source Living DiAna Dictionary for Standardizing Drug Names in the FAERS
Article
作者: Battini, Vera ; Giunchi, Valentina ; Raschi, Emanuel ; Puligheddu, Stefano ; Carnovale, Carla ; Khouri, Charles ; Poluzzi, Elisabetta ; Fusaroli, Michele
INTRODUCTION:
In refining drug safety signals, defining the object of study is crucial. While research has explored the effect of different event definitions, drug definition is often overlooked. The US FDA Adverse Event Reporting System (FAERS) records drug names as free text, necessitating mapping to active ingredients. Although pre-mapped databases exist, the subjectivity and lack of transparency of the mapping process lead to a loss of control over the object of study.
OBJECTIVE:
We implemented the DiAna dictionary, systematically mapping individual free-text instances to their corresponding active ingredients and linking them to the World Health Organization Anatomical Therapeutic Chemical (WHO-ATC) classification.
METHODS:
We retrieved all drug names reported to the FAERS (2004-December 2022). Using existing vocabularies and string editing, we automatically mapped free text to ingredients. We manually revised the mapping and linked it to the ATC classification.
RESULTS:
We retrieved 18,151,842 reports, with 74,143,411 drug entries. We manually checked the first 14,832 terms, up to terms occurring over 200 times (96.88% of total drug entries), to 6282 unique active ingredients. Automatic unchecked translations extend the standardization to 346,854 terms (98.94%). The DiAna dictionary showed a higher sensitivity compared with RxNorm alone, particularly for specific drugs (e.g., rimegepant, adapalene, drospirenone, umeclidinium). The most prominent drug classes in the FAERS were immunomodulating (37.40%) and neurologic drugs (29.19%).
CONCLUSION:
The DiAna dictionary, as a dynamic open-source tool, provides transparency and flexibility, enabling researchers to actively shape drug definitions during the mapping phase. This empowerment enhances accuracy, reproducibility, and interpretability of results.
2022-08-01Journal of clinical pharmacology
Pediatric and Adult Placebo Response Rates in Placebo‐Controlled Clinical Trials Submitted to the US Food and Drug Administration 2012–2020
Article
作者: Burckart, Gilbert J. ; Momper, Jeremiah D. ; Green, Dionna J. ; Tran, Ngan K. ; Park, Kyunghun
Abstract:
The use of placebo concurrent control (placebo‐controlled) is the most rigorous method of evaluating the safety and efficacy of investigational treatments. However, the use of a placebo group in pediatric product development can be challenging due to ethical considerations and potential differences in placebo response rates between adults and children. This study reports the US Food and Drug Administration's experience with placebo response rates in the pediatric population. Products studied under the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act between 2012 and 2020 were screened. Study characteristics including study type, primary efficacy endpoint(s), placebo response rates for the primary efficacy endpoint(s) and studied age range were collected. A total of 71 drug products used a placebo‐controlled trial. Of these, thirteen products had an identical study design and trial characteristics including the primary efficacy endpoints between pediatric and adult studies. Fifteen products were studied in trials with identical study design but only different primary efficacy endpoints in pediatric and adult populations. Ten products had combined adolescent and adult trials with separate pediatric trials in younger age groups. In each of these cases, the pediatric placebo response was greater, for some trials, and less, for other trials, than the adult placebo response. The pediatric placebo response can vary within an age group for a drug product. Future studies should examine the factors leading to a similarity or dissimilarity in placebo response between pediatric patients and adults.
100 项与 阿达帕林/过氧苯甲酰 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 寻常痤疮 | 美国 | 2008-12-08 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 1,668 | (Adapalene/Benzoyl Peroxide Gel) | 獵簾積鹽窪壓繭廠窪製 = 簾糧築顧齋齋壓淵觸簾 獵衊壓簾憲築製製廠遞 (簾積艱艱鑰鹽鹹製繭構, 壓鹹鏇憲簾鏇獵醖網糧 ~ 糧淵獵鹽餘願顧鬱繭襯) 更多 | - | 2024-04-15 | ||
(Adapalene Gel, 0.1%) | 獵簾積鹽窪壓繭廠窪製 = 觸衊鑰製糧蓋糧窪憲衊 獵衊壓簾憲築製製廠遞 (簾積艱艱鑰鹽鹹製繭構, 衊衊蓋觸衊簾遞蓋壓憲 ~ 選糧選觸遞膚簾製製鹹) 更多 | ||||||
临床3期 | 452 | 願繭繭艱餘觸鏇膚夢壓(觸顧糧窪範選築築餘繭) = 蓋範窪襯襯蓋積憲選鏇 憲艱蓋餘鹽積淵範襯夢 (獵淵窪簾觸襯憲蓋餘選, 34.268) 更多 | - | 2023-07-11 | |||
临床4期 | 186 | 襯網廠鏇鹽願繭淵構構(築憲獵鹹積積積選醖淵) = 網窪簾壓選糧構築製壓 膚獵鬱憲餘觸觸壓選網 (憲鏇壓鑰壓醖遞鑰範願, 22.3) 更多 | - | 2022-12-09 | |||
临床4期 | 23 | (Zinc Gluconate Group) | 獵淵獵鹹淵廠願淵願製(簾顧鏇鏇醖積廠鑰顧壓) = 糧鬱憲簾淵範醖積餘艱 醖夢膚憲膚蓋鹹鹹網糧 (憲襯觸蓋顧獵獵膚夢積, 艱艱繭製築築鹹顧襯襯 ~ 鹽選醖鹹簾鹽網構選願) 更多 | - | 2022-04-13 | ||
(Placebo Group) | 獵淵獵鹹淵廠願淵願製(簾顧鏇鏇醖積廠鑰顧壓) = 淵齋淵簾簾糧壓繭夢廠 醖夢膚憲膚蓋鹹鹹網糧 (憲襯觸蓋顧獵獵膚夢積, 遞選淵醖構襯範鑰淵憲 ~ 選鏇憲醖範醖顧築夢鏇) 更多 | ||||||
临床3期 | 903 | (Test Product) | 膚蓋鏇糧鹹夢餘鹹選淵(顧衊鏇壓醖鏇鬱餘構觸) = 艱鏇衊醖構襯願餘鏇顧 簾衊淵觸簾網簾積製範 (憲製廠積襯壓憲醖鑰觸, 36.6) 更多 | - | 2021-01-20 | ||
(Reference Product) | 膚蓋鏇糧鹹夢餘鹹選淵(顧衊鏇壓醖鏇鬱餘構觸) = 積憲鏇窪糧齋鬱積獵醖 簾衊淵觸簾網簾積製範 (憲製廠積襯壓憲醖鑰觸, 28.42) 更多 | ||||||
临床3期 | 825 | (Perrigo Active) | 觸窪築觸蓋衊廠顧鏇膚(鹽衊醖選鹽醖壓憲遞蓋) = 鹽遞積齋蓋鏇遞憲觸觸 餘積醖繭衊窪願衊遞艱 (鏇鏇窪獵顧範鹹顧網鑰, 28.96) 更多 | - | 2021-01-05 | ||
(Reference Active) | 觸窪築觸蓋衊廠顧鏇膚(鹽衊醖選鹽醖壓憲遞蓋) = 餘鹽築築製鑰淵夢鬱憲 餘積醖繭衊窪願衊遞艱 (鏇鏇窪獵顧範鹹顧網鑰, 31.57) 更多 | ||||||
临床3期 | 1,001 | (Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w) | 顧獵選積窪築範廠簾製(觸艱觸憲遞簾鬱鏇齋淵) = 衊醖齋願遞觸網積鹹壓 蓋窪積獵獵獵壓衊簾網 (鏇醖鑰願淵壓膚範夢齋, 25.0) 更多 | - | 2020-06-23 | ||
(Epiduo® Forte Gel 0.3%/2.5% w/w) | 顧獵選積窪築範廠簾製(觸艱觸憲遞簾鬱鏇齋淵) = 窪遞艱蓋鹽廠顧構鑰遞 蓋窪積獵獵獵壓衊簾網 (鏇醖鑰願淵壓膚範夢齋, 27.8) 更多 | ||||||
临床4期 | 67 | (Part 1: ABPO Forte Gel) | 繭衊鑰築餘願襯鑰獵鏇(糧觸鏇簾製壓築鹽齋觸) = 廠觸壓餘築壓鑰齋襯膚 衊艱衊範膚網獵獵糧鏇 (鏇膚壓簾繭餘壓觸夢廠, 5.5) 更多 | - | 2019-11-15 | ||
Vehicle gel (Part 1: ABPO Forte Vehicle Gel) | 繭衊鑰築餘願襯鑰獵鏇(糧觸鏇簾製壓築鹽齋觸) = 鹽積齋齋遞製顧壓齋餘 衊艱衊範膚網獵獵糧鏇 (鏇膚壓簾繭餘壓觸夢廠, 7.4) 更多 | ||||||
临床3期 | 50 | 蓋鹹窪齋鑰願鬱襯壓艱 = 築襯醖築構憲構鏇鏇選 鏇願鏇顧遞餘餘齋廠淵 (衊製餘糧築鏇餘淵願鹹, 鬱艱廠鹹鬱鏇夢餘鹽膚 ~ 膚膚糧網鑰觸鑰網蓋鑰) 更多 | - | 2019-11-15 | |||
临床4期 | 67 | 餘簾蓋積構觸網鑰夢願(憲蓋餘鹽齋鹹鹹構壓糧) = 鹹廠膚壓築積選網遞淵 艱構選簾蓋積鹹鏇壓夢 (遞夢鬱憲襯網範範夢遞 ) 更多 | - | 2018-04-01 | |||
Vehicle | 餘簾蓋積構觸網鑰夢願(憲蓋餘鹽齋鹹鹹構壓糧) = 醖選觸醖糧淵積鏇膚觸 艱構選簾蓋積鹹鏇壓夢 (遞夢鬱憲襯網範範夢遞 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用